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Abstract: The cancer secretome is a rich repository of useful information for both cancer biology
and clinical oncology. A better understanding of cancer secretome is particularly relevant for
pancreatic ductal adenocarcinoma (PDAC), whose extremely high mortality rate is mainly due to
early metastasis, resistance to conventional treatments, lack of recognizable symptoms, and assays
for early detection. TP53 gene is a master transcriptional regulator controlling several key cellular
pathways and it is mutated in ~75% of PDACs. We report the functional effect of the hot-spot p53
mutant isoforms R175H and R273H on cancer cell secretome, showing their influence on proliferation,
chemoresistance, apoptosis, and autophagy, as well as cell migration and epithelial-mesenchymal
transition. We compared the secretome of p53-null AsPC-1 PDAC cells after ectopic over-expression
of R175H-mutp53 or R273H-mutp53 to identify the differentially secreted proteins by mutant p53.
By using high-resolution SWATH-MS technology, we found a great number of differentially secreted
proteins by the two p53 mutants, 15 of which are common to both mutants. Most of these secreted
proteins are reported to promote cancer progression and epithelial-mesenchymal transition and might
constitute a biomarker secreted signature that is driven by the hot-spot p53 mutants in PDAC.
Keywords: mutant p53; pancreatic adenocarcinoma; secretome; proteomics; oncogenes; gain-of-function
1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer; it is
characterized by poor prognosis, with a dismal overall five-year survival rate of ~5% [1,2]. A typical
Biomolecules 2020, 10, 884; doi:10.3390/biom10060884 www.mdpi.com/journal/biomolecules
Biomolecules 2020, 10, 884 2 of 21
feature of PDAC is the lack of early phase specific symptoms that leads to a late-stage diagnosis.
In addition, the absence of early biomarkers, detection methods, and chemoresistance are the main
drivers of poor prognosis in PDAC [3,4]. Chemoresistance is primarily caused by key genetic alterations,
which favour disorders in the apoptotic pathway [3]. One of the most important proteins involved
in DNA damage repair and apoptosis is the tumor suppressor protein p53 (TP53), which regulates
a wide range of cellular biological processes to prevent tumor formation by killing or delaying the
growth of neoplastic cells [5]. The importance of the p53 pathway in tumor suppression is also
highlighted by the observation that TP53 mutations are associated to poor prognosis [6] and they are
present in about half of all human cancers, reaching even ~75% of PDAC patients [7,8]. The great
majority of p53 alterations are missense mutations that are localized in the DNA binding domain,
which result in the expression of full-length mutant p53 isoforms [9]. The most frequent p53 alterations
are missense mutations in the DNA binding domain (DBD), called hot-spot mutants, which cause
the expression of full-length p53 mutant isoforms. These mutations in the DBD are grouped into
two main types: conformational mutations, such as mutp53-R175H, and contact mutations, such
as mutp53-R273H, which cause structural modifications in the binding domain or affect the DNA
binding ability of the protein, respectively [10]. Both kinds of mutations alter p53’s interaction with
its consensus DNA-binding sequence, negatively impacting the activation of tumor suppressor wild
type-p53 target genes.
In addition, these mutants can acquire new oncogenic functions and they are named
gain-of-function (GOF) mutants. In fact, although they lose the capability to bind DNA and regulate
wtp53-target genes, they can regulate the transcription of a different set of genes that induce cancer
aggressiveness. This is achieved through direct interaction with various transcription factors or
repressors in the transcriptional complex. This results in the development of the typical hallmarks of
cancer cells carrying the mutant TP53 gene, such as chemoresistance [11], metabolic alterations [12,13],
and genomic instability [14]. Furthermore, mutant p53 isoforms strongly accumulate in cells as a
result of a reduction in the rate of mutant p53 protein degradation due to its inability to induce the E3
ubiquitin-protein ligase MDM2 [15], thus amplifying the oncogenic effects of the protein.
Many recent studies reveal the role of p53 mutant proteins in the modification of the
tumor microenvironment and secretome of cancer cells, altering the secretion of inflammatory
cytokines, affecting the crosstalk between cancer and stromal cells, and increasing the extracellular
acidification [16–18]. Cancer aggressiveness is strongly dependent on the composition of the
extracellular microenvironment, which is itself affected by the release of proteins by the cancer
cells. Indeed, secreted proteins may promote carcinogenesis, favoring key roles, such as cell signaling,
communication and migration [19,20]. Thus, the secretome of cancer cells represents an unique
opportunity to collect and identify several secreted macromolecules and may be considered a valuable
source for biomarker discovery and the identification of novel therapeutic targets [18,21].
In the present study, we investigate the functional effect of mutp53-driven secretome of PDAC
cells, demonstrating its impact on several hallmarks of cancer cells carrying the mutant TP53 gene, such
as hyper-proliferation, chemoresistance, inhibition of apoptosis and autophagy, cell migration, and
epithelial-to-mesenchymal transition. In order to identify a mutp53-dependent signature of secreted
proteins by PDAC cells, a proteomics approach has been used. We identified 15 hypo- or hyper-secreted
proteins in common to both R175H and R273H hot-spot mutant p53 isoforms. These results definitively
clarify the functional impact of mutp53-driven secretome in PDAC aggressiveness and provide crucial
insights on the identification of mutp53-dependent PDAC secretome.
2. Materials and Methods
2.1. Chemicals
Gemcitabine (2′,2′-difluoro-2′-deoxycytidine; GEM) was provided by Accord Healthcare
(Milan, Italy) and it was solubilized in sterile water.
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2.2. Cell Culture
PDAC cell line AsPC-1 (p53-null) was grown in RPMI 1640, while lung cancer cell line H1299
(p53-null) was cultured in DMEM medium (Life Technologies, Milan, Italy). Both culture media were
supplemented with 10% FBS, and 50 µg/mL gentamicin sulfate (BioWhittaker, Lonza, Bergamo, Italy).
AsPC1 was purchased by ATCC (Manassas, VA, USA), while both of the mock clone and clone stably
expressing mutant p53-R273H of the p53-null H1299 cells were kindly provided by Dr. Riccardo Spizzo
(Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy). The adherent cells were
incubated at 37 ◦C with 5% CO2.
2.3. Transient Transfection Assay
AsPC-1 cells were seeded in 96-well or in six-well plates. Wild type or mutant p53 ectopic expression
in p53-null cancer cells was obtained by transfecting pcDNA3-mutp53R273H, pcDNA3-mutp53R175H,
or pCMV-wild type p53 expression vectors or their relative negative control (pcDNA3 or pCMV).
Transfections were carried out using Lipofectamine 3000 (Thermo Fisher Scientific, Milan, Italy) for
48 h, according to the manufacturer’s instructions.
2.4. Cell Proliferation Assay
AsPC-1 cells were seeded in 96-well plates (8 × 103 cells/well). Forty-eight hours later, cell growth
was measured by Crystal Violet assay (Sigma, Milan, Italy) according to the manufacturer’s protocol,
and the absorbance was measured by spectrophotometric analysis (A595 nm).
2.5. Apoptosis Assay
The cells were seeded in 96-well plates (8 × 103 cells/well). Forty-eight hours later, cells were
fixed with 2% paraformaldehyde in PBS for 15 min. at room temperature, washed twice with PBS,
and then stained with annexinV/FITC (Bender MedSystem, Milan, Italy) in binding buffer (10 mM
HEPES/NaOH pH 7.4, 140 mM NaCl, and 2.5 mM CaCl2) for 10 min. at room temperature in the dark.
The cells were then washed with binding buffer and fluorescence was measured using a multimode
plate reader (Ex485 nm and Em535 nm) (GENios Pro, Tecan, Milan, Italy). The values were normalized
on cell proliferation by Crystal Violet assay.
2.6. Autophagosome Formation Assay
The cells were stained with the fluorescent probe monodansylcadaverine (MDC; Sigma, Milan,
Italy) to quantify the induction of autophagy, since MDC is a maker for acidic vesicular organelles
(AVOs), as autophagic vacuoles and autolysosomes. Briefly, cells were seeded in 96-well plates
(5 × 103 cells/well) and, 48 h later, cells were incubated in culture medium containing 50 µM MDC at
37 ◦C for 15 min. Cells were then washed with Hanks buffer (20 mM Hepes pH 7.2, 10 mM glucose,
118 mM NaCl, 4.6 mM KCl, and 1 mM CaCl2) and fluorescence was measured using a multimode
plate reader (Ex340 nm and Em535 nm) (GENios Pro, Tecan, Milan, Italy). The values were normalised
on cell proliferation by Crystal Violet assay.
2.7. Wound-Closure Cell Migration Assay
AsPC-1 cells were seeded in six-well plate (6× 105 cells/well). A scratch was made across the center
of the AsPC1 p53-null monolayer cells using a sterile 200-µL pipette tip. Subsequently, the cells were
washed with PBS to remove the detached cells and incubated with conditioned medium (CM) released
by transfected AsPC-1 cells for 48 h. Cell migration was observed in time-lapse (EVOS). Images of
cells movement were captured every 2 h for 48 h and were further analyzed quantitatively using NIH
ImageJ computing software (http://rsb.info.nih.gov/nih-image/). Migration ability as relative migration
distance (RMD) was evaluated using the following formula: RMD (%) = 100 (A − B)/A, with A and B
representing the width of cell scratches at time 0 and after 48 h of incubation, respectively.
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2.8. FACS Analysis
The cells were trypsinized, washed with PBS, and then incubated with anti-human CD325
(N-Cadherin) antibody that was conjugated with PE (BioLegend, San Diego, CA, USA; Clone 8C11) or
anti-human CD324 (E-Cadherin) antibody conjugated with PE (BioLegend; Clone 67A4). Unstained
cells were used as negative control.
Approximately 10,000 gated events were acquired for each sample on a FACSCanto cytometer
(Becton Dickinson, Franklin Lakes, NJ, USA). Flow cytometry data were analyzed using FlowJo
software (v10; TreeStar, Ashland, OR, USA). Dead cells and debris were excluded on the basis of
forward-scatter and side-scatter. N- and E-Cadherin expression was calculated as fold change: median
fluorescence intensity (MFI) of stained sample normalized with respect to the MFI of unstained sample.
2.9. Immunoblot Analysis
The cells were harvested, washed in PBS, and solubilized in lysis buffer in the presence of
phosphatase and protease inhibitors (50 mM Tris–HCl pH 8, 150 mM NaCl, 1% Igepal CA-630,
0.5% Na-Doc, 0.1% SDS, 1 mM Na3VO4, 1 mM NaF, 2.5 mM EDTA, 1 mM PMSF, and 1× protease
inhibitor cocktail). After incubation on ice for 30 min., the lysates were centrifuged at 14,000× g
for 10 min. at 4 ◦C and the supernatant fractions were used for Western blot analysis. Protein
concentration was measured by Bradford reagent (Pierce, Milan, Italy) using bovine serum albumin
as a standard. The protein extracts (20 µg/lane) were resolved on a 12% SDS-polyacrylamide gel
and electro-blotted onto PVDF membranes (Millipore, Milan, Italy). After transferring proteins onto
PVDF membranes, Amido Black 1X Staining Solution (Sigma–Aldrich #A8181) was used to confirm
equal protein loading in different lanes. Briefly, the membranes were covered with Amido Black and
stain by gentle shaking for one minute at room temperature; after that, membranes were de-stained
by placing in an aqueous solution containing 25% isopropanol and 10% acetic acid for 30 minutes
at room temperature. The membranes were blocked in 5% low-fat milk in TBST (50 mM Tris pH
7.5, 0.9% NaCl, 0.1% Tween 20) for 1 h at room temperature and probed overnight at 4 ◦C with
a mouse polyclonal anti-p53 (1:2000) (Santa Cruz, #sc-263), rabbit monoclonal anti-glyceraldehyde
3-phosphate dehydrogenase (GAPDH) (1:1000) (Cell Signaling, #5174S) antibodies. Mouse monoclonal
anti-vimentin (1:200) (Santa Cruz, #sc-373717) was used to detect the expression levels of secreted
vimentin in protein extracts that were derived from conditioned medium by a protein extraction method
described in the next paragraph. Horseradish peroxidase conjugated anti-mouse or anti-rabbit IgGs
(1:8000 in blocking solution) (Upstate Biotechnology, Milan, Italy) were used as secondary antibodies.
Immunodetection was carried out using chemiluminescent substrates (Amersham Pharmacia Biotech,
Milan, Italy) and recorded using a HyperfilmECL (Amersham Pharmacia Biotech). The ECL (Enhanced
ChemiLuminescence) results were scanned and the amount of each protein band was quantified using
NIH Image J software.
2.10. Protein Extraction from Conditioned Medium (CM)
The day after transient transfection, the AsPC-1 cells were washed six times in PBS
(phosphate-buffered saline) and then incubated in serum-free RPMI for 22 h. This serum-free
time period of incubation has been chosen on the basis of our previous investigations in order to avoid
cell injury. Cell viability, as determined with 0.4% trypan blue solution (Thermo Fischer Scientific), was
higher than 95%. The media containing secreted proteins were collected by centrifugation at 1000× g
for 10 min. to pellet floating cells and were defined as conditioned media (CM). After the addition of
1× protease inhibitor cocktail (Roche), CM were centrifuged again at 17,000× g for 20 min. at 4 ◦C to
pellet the remaining cell debris. The proteins in the CM were precipitated overnight at −20 ◦C with 4
volumes of ice-cold acetone. The pellets were then collected by centrifugation at 17,000× g for 20 min.
at 4 ◦C and then resuspended in 100 mM ammonium bicarbonate (NH4HCO3). Protein concentrations
were determined using BCA protein assay (Sigma).
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2.11. In-Solution Digestion
Before SWATH-MS analysis, the CM proteins were digested following the protocol provided by
the manufacture (Applied Biosystem). Briefly, samples were prepared to have 100 µg of protein in a
final volume of 25 µL of 100 mM NH4HCO3. The proteins were reduced using 2.5 µL of dithiothreitol
(200 mM DTT stock solution) (Sigma) at 90 ◦C for 20 min. and alkylated with 10 µL of Cysteine Blocking
Reagent (Iodoacetamide, IAM, 200 mM; Sigma) for 1 h at room temperature in the dark. DTT stock
solution was then added to destroy the excess of IAM. After dilution with 300 µL of water and 100 µL
of NH4HCO3 to raise pH, 5 µg of trypsin (Promega, Sequence Grade) was added and digestion was
performed overnight at 37 ◦C. Trypsin activity was stopped by adding 2 µL of neat formic acid and the
digests were dried by Speed Vacuum [21].
2.12. Data Acquisition
The digested samples were analyzed on a micro-LC Eksigent Technologies (Dublin, OH, USA)
interfaced to a 5600+ TripleTOF mass spectrometer system (AB Sciex, Concord, ON, Canada) that was
equipped with a DuoSpray Ion Source and a CDS (Calibrant Delivery System). The LC column was a
Halo Fused C18 (AB Sciex, Concord, ON, Canada). The mobile phase was a mixture of 0.1% (v/v) formic
acid in water (A) and 0.1% (v/v) formic acid in acetonitrile (B), eluting at a flow-rate of 15.0 µL min.−1
at an increasing concentration of solvent B from 2% to 40% in 30 min. The injection volume was 4.0 µL
and the oven temperature was set at 40 ◦C. For identification purposes, the samples were subjected to
data dependent analysis (DDA): the mass spectrometer operated using a mass range of 100–1500 Da
(TOF scan with an accumulation time of 0.25 s), followed by a MS/MS product ion scan from 200
to 1250 Da (accumulation time of 5.0 ms) with the abundance threshold set at 30 cps (35 candidate
ions can be monitored during every cycle). The ion source parameters in electrospray positive mode
were set, as follows: curtain gas (N2) at 25 psig, nebulizer gas GAS1 at 25 psig, and GAS2 at 20 psig,
ionspray floating voltage (ISFV) at 5000 V, source temperature at 450 ◦C, and declustering potential
at 25 V. For the quantification, the samples were subjected to cyclic data independent analysis (DIA)
of the mass spectra, using a 25-Da window: the mass spectrometer was operated, such that a 50-ms
survey scan (TOF-MS) was performed and subsequent MS/MS experiments were performed on all
precursors. These MS/MS experiments were performed in a cyclic manner while using an accumulation
time of 40 ms per 25-Da swath (36 swaths in total) for a total cycle time of 1.5408 s [22]. The ions were
fragmented for each MS/MS experiment in the collision cell while using the rolling collision energy.
The MS data were acquired with Analyst TF 1.7 (AB SCIEX, Concord, ON, Canada). Two DDA and
three DIA acquisitions were performed.
2.13. Protein Database Search
The DDA files were searched using Protein Pilot software v. 4.2 (AB SCIEX, Concord, ON,
Canada) and Mascot v. 2.4 (Matrix Science Inc., Boston, MA, USA). The DIA files were converted
to pseudo-MS/MS spectra with DIA-Umpire software and they were searched as DDA files [23,24].
Trypsin as digestion enzyme was specified for both the software. For Mascot we used two missed
cleavages, the instrument was set to ESI-QUAD-TOF, and the following modifications were specified
for the search: carbamidomethyl cysteins as fixed modification and oxidized methionine as variable
modification. A search tolerance of 0.08 Da was specified for the peptide mass tolerance, and 10 ppm
for the MS/MS tolerance. The charges of the peptides to search for were set to 2 +, 3 +, and 4 +, and the
search was set on monoisotopic mass. The UniProt Swiss-Prot reviewed database containing human
proteins (version 2015.07.07, containing 42131 sequence entries) was used and a target-decoy database
search was performed. False Discovery Rate was fixed at 1%.
Biomolecules 2020, 10, 884 6 of 21
2.14. Protein Quantification
MS1 (precursor ion masses) and MS2 (fragment ion masses) chromatogram based quantitation
was carried out in Skyline 3.1, an open source software project (http://proteome.gs.washington.edu/
software/skyline) [25]. Spectral libraries were generated in Skyline from database searches. All of the
raw files acquired in DIA were directly imported into Skyline and MS1 precursor ions and MS/MS
fragment ions were extracted for all peptides present in the MS/MS spectral libraries. Quantitative
analysis was based on extracted ion chromatograms (XICs) for the top three resulting precursor ion
peak areas e.g., M, M + 1, and M + 2 (MS1) and on XICs of up to three MS/MS fragment ions, typically
y- and b-ions, matchingspecific peptides present in the spectral libraries. For statistical analysis of
quantitative differences of proteins and peptides between samples, MSstats (v.2.0), an open-source
R-based package [26], was used.
2.15. Bioinformatics and Statistics Software
The potential secretion pathways of regulated proteins were predicted with the SecretomeP 2.0
server (http://www.cbs.dtu.dk/services/SecretomeP/) for classical and non-classical secretion, while the
localization of signal peptide cleavage sites were predicted with SignalP v.5.0 (http://www.cbs.dtu.dk/
services/SignalP/) [27].
The regulated proteins were analyzed using the STRING database (v.11.0) (http://string-db.org),
which is a database of known and predicted protein-protein interactions [28]. The Cytoscape (v.3.7.2)
ClueGO (v.2.5.4) plugin was used to visualize the enriched pathways associated with the Kyoto
Encyclopaedia of Genes and Genome (KEGG) database [29]. In brief, KEGG pathways were explored
with medium specificity and a kappa score of 0.4. An enrichment/depletion method with a two-sided
hypergeometric test was applied, correct with the Bonferroni step down for each p-value calculation.
Enriched pathways with a p-value < 0.05 were considered to be significant. Functional annotation
of identified proteins was employed while using the Database for Annotation, Visualization, and
Integrated Discovery (DAVID) (v.6.8) (http://david.abcc.ncifcrf.gov/) to identify gene ontology (GO)
biological processes (BPs), molecular function (MFs), and cellular component (CCs). The BPs, MFs, and
CCs that were enriched by the list of proteins were identified as the ones with p-value < 0.01 calculated
by DAVID [30].
2.16. Statistical Analysis
ANOVA analysis was performed by GraphPad Prism 5 software. p value < 0.05 was indicated as
being statistically significant. Values are the means of three independent experiments (± SD).
3. Results
3.1. Cancer Cell Secretome Driven by mutant p53 Induces Hyper-Proliferative Effects
We aimed to study the role of mutp53-driven secretome in cancer cell aggressiveness to investigate
whether mutant p53 may influence the secretome of PDAC cells. We induced the exogenous expression
of R273H or R175H mutp53 isoforms in p53-null AsPC-1 PDAC cells by using liposome-mediated
transient transfection assay, as summarized in Figure 1A. Forty-eight hours later, we checked the effective
over-expression of p53 in AsPC-1 by Western blotting and functionally analyzed the hyper-proliferative
effect induced by mutant p53 isoforms, as compared to mock or wt-p53 (Figure 1B). Subsequently,
AsPC-1 transfected cells were washed in PBS and then incubated in fresh culture medium for further 22 h
to accumulate secreted proteins. This conditioned medium (CM) released by transfected AsPC-1 cells
was transferred to new p53-null AsPC-1 cells, which were thus cultivated in wtp53- or mutp53-driven
secretome for 48 h in order to study the functional effects of secretome driven by GOF R175H and
R273H mutp53 isoforms. Figure 1C shows that both R175H and R273H p53 mutants are able to induce
AsPC-1 cell hyper-proliferation through their mutp53-driven CM, as compared to their negative mock
control or to wtp53-CM. Interestingly, in accordance with the tumor suppressor role of wild type p53,
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the wtp53-driven CM showed an inhibitory effect on cell growth. The absence of extracellular p53 in
mutp53- or wtp53-driven CM was proved by Western blotting and then further confirmed by mass
spectrometry analysis. Altogether, these data demonstrate that GOF mutant p53 isoforms can also
exert their hyper-proliferative effects on cancer cells through the alteration of their secretome.
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(A) A summary model of the approach used in this study: p53-null AsPC-1 cells were transfected with
plasmids for R273H or R175H mutant p53 over-expression or its mock vector for 48 h. Then, AsPC-1
transfected cells were w shed in PBS o remove liposomes and ncubate with fresh culture medium
for further 22 h to accumulate secreted proteins. After that, the conditioned medium (CM) of AsPC-1
transfected cells was transferred to untransfected p53-null AsPC-1 cells. After 48 h, several biological
phenomena listed in the figure were investigated in AsPC-1 cells bearing mutp53-driven CM. (B) Cell
growth was measured by Cristal Violet ass in 53-null AsPC-1 cells transfected for over-expression
of wtp53, R175H or R273H mutp53. Accompanying Western blotting of p53 a d of GAPDH for control
loading are reported. Statistical analysis * p < 0.05 R175H vs Mock; # p < 0.05 R273H vs Mock; $ p < 0.05
wtp53 vs Mock. (C) Cell growth was measured by Cristal Violet assay in untransfected p53-null AsPC-1
cells cultivated with wtp53-, R175H- or R273H-CM. Accompanying Western blotting of p53 and amido
black staining are reported. Statistical analysis * p < 0.05 CM-R175H vs CM-Mock; # p < 0.05 CM-R273H
vs CM-Mock; $ p < 0.05 wtp53 vs CM-Mock.
3.2. Mutp53-Driven Secretome Mediates Anti-Apoptotic, Anti-Autophagic and Chemoresistance Effects
We tested whether CM-R175H and CM-R273H were also able to induce other typical hallmarks
induced by intracellular GOF mutant p53 isoforms, as the inhibition of cell death-related phenomena
(i.e., apoptosis and autophagy) and the stimulation of chemoresistance to the standard drug gemcitabine
to better investigate the effects of mutant p53 secretome. Figure 2A shows that mutp53-derived CM was
able to counteract apoptosis in p53-null AsPC-1 cells, in accordance with the well-known antiapoptotic
effect of intracellular mutant p53 isoforms [31], which indicated that mutant p53 is also able to
counteract apoptosis by promoting the secretion of some molecules that discourages cell death.
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Figure 2. Mutp53-driven secretome mediates anti-apoptotic, anti-autophagic and chemoresistance
effects. (A) Apoptosis was determined by the annexinV/FITC binding assay in AsPC-1 cultivated with
mutp53-derived CM. The annexinV-FITC fluorescence intensity was measured by using a multimode
plate reader and reported as arbitrary units (a.u.). (B) Autophagosome formation assay was determined
by intracellular staining using the MDC probe in AsPC-1 cultivated with mutp53-derived CM. Statistical
analysis * p < 0.05 CM-R175H vs M-Mock; # p < 0.05 CM-R273H s CM-Mock. (C) Cell growth was
analyz d by Cristal Violet assay in AsPC-1 cultivated with mutp53-derived C treated with 1 µ GEM
for 48 h. Statistical analysis ˆ p < 0.05 CM-R273H + GEM vs CM-Mock + GEM; ◦ p < 0.05 CM-Mock +
GEM vs CM-Mock.
Moreover, since we previously demonstrated that GOF mutant p53 proteins blocked the autophagic
flux by the regulation of so e molecular pathways, as AMPK, AKT/mTOR, and some crucial
autop agy-related genes (ATGs) [32,33], w wondered whether mutan p53 might also counteract
autophagy by secr t me alteration. F gure 2B shows that the CM released by R175H- o R273H-mutp53
AsPC-1 cancer cells decreases the amount of intracellular autophagic vesicles, when compared to
p53-null driven CM.
Furthermore, our previous data showed that mutant p53 can stimulate the chemoresistance
of PDAC cells to the drug gemcitabine (GEM) [11]. Thus, we investigated whether mutp53-driven
secretome may also be able to reduce cancer cells sensitivity to GEM. Figure 2C shows that GEM
inhibited cell growth of AsPC-1 cells that were cultivated with mock-derived CM, while the CM
derived by R273H mutant p53 AsPC-1 cells counteracted the therapeutic effect of GEM, as compared
to its mock control, representing an important aspect to be further considered for clinical therapeutic
studies. Overall, these data provide evidence that mutant p53 proteins influence the secretion of
components that contribute to cancer cell growth and resist cell death-related phenomena, such as
apoptosis, autophagy, and anticancer drug exposure.
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3.3. Mutp53-Driven Secretome Stimulates Cancer Cell Migration and Epithelial-to-Mesenchymal Transition
Because GOF mutant p53 isoforms can stimulate cancer cell migration, we also investigated
whether mutp53-induced modulation of secretome can have a role in this phenomenon [17]. Using the
same methodological approach described in Figure 1A, we discovered that CM-R175H and CM-R273H
are able to favor the migration of AsPC-1 cells (Figure 3A). In particular, we observed a faster wound
closure in p53-null ASPC-1 cells cultivated with R175H or R273H mutant p53-driven secretome, as
compared to CM derived from their mock control (CM-mock). We also used stable clones of p53-null
lung cancer H1299 cells non-expressing (mock) or constitutively expressing the R273H mutant p53
isoform, which were previously used as a valuable cell model to study the oncogenic effects of mutant
p53, in order to further straighten these data [33]. As control of mutant p53 expression and functionality,
in Figure S1 we report the cellular hyper-proliferative effect and the mutant p53 expression level
observed in mock and R273H-mutp53 clones of H1299 cells. Concerning the migration assay, Figure 3B
shows also that the secretome derived by H1299 cancer cells stably expressing R273H mutant p53
(CM-H1299 R273H) induced cell migration of AsPC-1 p53-null cells as compared to mock control
(CM-H1299 mock), further supporting the results on AsPC-1 secretome shown in Figure 3A.
Finally, we investigated whether GOF mutp53-driven secretome contributes to another typical
feature that is induced by mutant p53, namely epithelial-to-mesenchymal transition (EMT) of cancer
cells, which is a phenomenon strictly connected to cancer cell migration [34,35]. In Figure 3C, we show
that R175H mutant p53 increased N-cadherin and decreased E-cadherin protein expression in cancer cell
membrane, as compared to mock, thus markedly altering the N/E cadherin ratio, a typical feature of EMT.
Intriguingly, CM-derived by AsPC-1 overexpressing R175H mutant p53 is also able to induce the same
regulation of N- and E-cadherin expression level in cancer cell membrane, as compared to CM-mock
derived by AsPC-1 cells. Consequently, the N/E cadherin ratio was higher in AsPC-1 cells cultivated
with CM-R175H as compared to the same cells that were cultivated with CM-mock. Since N-cadherin
promotes motility, invasion, and produces a scattered phenotype with EMT, in association with a
reduction in the expression of E-cadherin [36,37], our results suggest that proteins that are secreted by
mutant p53-expressing cancer cells have a crucial role in EMT transition, thus sustaining the migration
and aggressiveness of cancer cells.
3.4. Identification of Secreted Proteins from Mutp53-Driven Secretome
After the investigation of the oncogenic functions of mutp53-driven secretome, we aimed to
identify the main differentially secreted proteins by mutant p53 isoforms in PDAC. Thus, we analyzed
the protein composition of the CM released by AsPC-1 cells expressing GOF mutp53 as compared to
p53-null AsPC-1 cells (mock). After the transfection period (48 h), the cells were washed to remove
DNA:liposome complexes and they were cultured for a further 22 hours to accumulate secreted proteins
in serum-free culture medium to avoid protein cross-contamination by serum. Notably, this serum-free
culture period has been identified as the maximum time period without delay of cell growth or signals
of cell death (Figure S2) to avoid undiscriminating cellular lysis. A peptide liquid chromatography
separation followed by mass spectrometry analysis and database search with Protein Pilot and Mascot
was then performed. SWATH-MS analyses were performed in triplicates for each analyzed sample
and they were imported in the Skyline software to perform the label-free quantification and the
identification of regulated proteins. We identified 194 proteins in CM-R273H and 228 proteins in
CM-R175H transfected cells. The major part of them (165 proteins) were in common between the two
mutp53-driven secretomes of AsPC-1 cells. The semi-quantitative proteomic analysis showed that
45 proteins resulted in being significantly modulated in the CM-R175H (Table S1) and 58 proteins
were significantly modulated in CM-R273H (Table S2) as compared to the mock control (CM-mock).
Further analyzing the modulated proteins, we identified 15 differentially secreted proteins in common
between CM-R175H and CM-R273H (Table 1). Among these proteins that can better represent a
common signature of secretome alteration driven by different GOF p53 mutant isoforms, there are
several interesting proteins, such as growth factors (IGFBP1), histone proteins (HIST1H3A, HIST1H4A,
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HIST2H2AA3, HIST2H3A, and H2AFV), endothelial protein C receptor (EPCR), and others, which are
commented in the Discussion section. We analyzed by western blotting the extracellular expression
level of vimentin (VIM) in CM-mock, CM-R273H, and CM-R175H of AsPC-1 cells, confirming the
hyper-secretion of VIM induced by both mutant p53 isoforms in order to validate mass spectrometry
data (Figure S3). We have further investigated whether these 15 proteins were already identified in
PDAC-derived exosomes and seven of them, namely PROCR, TIMP1, EZR, PSAP, VIM, CLSTN1 and
CFL1, were detected in the proteome of pancreatic cancer exosomes using mass spectrometry [38],
which suggests their roles as key signaling molecules.
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Table 1. Fifteen common secreted proteins by both R273H or R175H mutant p53 isoforms expressed in
AsPC-1 cells and identified by using high-resolution SWATH-MS technology (p < 0.05).
Accession Name Entry Protein Names Gene
Fold Change
versus Mock (FC)
R273H R175H
IBP1_HUMAN P08833 Insulin-like growth factor-bindingprotein 1 IGFBP1 4.49 3.03
EPCR_HUMAN Q9UNN8 Endothelial protein C receptor PROCR 2.42 1.49
TIMP1_HUMAN P01033 Metalloproteinase inhibitor 1 TIMP1 2.18 1.30
DCD_HUMAN P81605 Dermcidin DCD 1.94 1.37
EZRI_HUMAN P15311 Ezrin EZR 1.82 2.48
SAP_HUMAN P07602 Prosaposin PSAP 1.64 1.42
VIME_HUMAN P08670 Vimentin VIM 1.47 2.32
CSTN1_HUMAN O94985 Calsyntenin-1 CLSTN1 1.43 2.51
TAD2B_HUMAN Q86TJ2 Transcriptional adapter 2-beta TADA2B 1.39 1.37
COF1_HUMAN P23528 Cofilin-1 CFL1 1.35 1.52
H4_HUMAN P62805 Histone H4 HIST1H4A 0.54 0.76
H31_HUMAN P68431 Histone H3.1 HIST1H3A 0.43 0.46
H32_HUMAN Q71DI3 Histone H3.2 HIST2H3A 0.41 0.40
H2AV_HUMAN Q71UI9 Histone H2A.V H2AFV 0.33 0.45
H2A2A_HUMAN Q6FI13 Histone H2A type 2-A HIST2H2AA3 0.32 0.45
3.5. Bioinformatic Analyses and Interaction Networks of Mutp53-Driven Secreted Proteins
Proteins that were detected in secretome samples were analyzed with the SignalP 5.0 and
SecretomeP 2.0 prediction algorithms in order to determine which proteins are predicted to be secreted
via classical (signal peptide-directed) or non-classical secretion mechanisms. The SignalP software
allowed for defining the species that are secreted through the classical endoplasmic reticulum (ER)/Golgi
pathway: all of the proteins lacking the presence of the classical signal peptide for the translocation
to the ER, were then tested by SecretomeP 2.0 software for the putative export through one of the
so-called non-classical secretory pathways (Table S3). Out of the 194 proteins that were detected in
CM-R273H, secretory signal peptides were present in 42 (22%) of these proteins (SignalP D score >0.45)
and 33 (17%) were identified as non-classically secreted proteins (SecretomeP NN score >0.6, with
no secretory signal present). Of the 228 proteins that were detected in CM-R175H transfected cells,
secretory signal peptides were present in 36 (16%) (SignalP D score >0.45) and 33 (15%) were identified
as non-classically secreted proteins (SecretomeP NN score >0.6, with no secretory signal present).
Together, these predictions account for ∼55% and ∼31% of the secreted proteins detected in CM of
R273H and of R175H transfected AsPC-1 cells, respectively. Thus, these algorithms are not able to
predict which subsets of proteins may be released from cells: in fact, proteins from various subcellular
locations may be released by different mechanisms to play a biological role outside of the cell. This
is also confirmed by the fact that, out of the 257 secreted proteins, 204 (79%) have been previously
identified in cancer secretomes (www.cancersecretome.org).
The functional annotation of enriched secreted proteins was examined using DAVID software by
performing enrichment analysis of biological processes (BPs), molecular functions (MFs), and cellular
components (CCs) (Figure 4A,B).
Interestingly, the most significantly enriched BPs categories included cell-cell adhesion (22% of
proteins), canonical glycolysis (9%), glycosaminoglycan metabolic process (13%) and extracellular
matrix disassembly (10%). Moreover, the DAVID software associated the secretome profile with
some interesting molecular functions, such as glycoprotein binding (10%) and insulin-like grow factor
II binding (5%). Finally, the enrichment analysis of CCs revealed that enriched secreted proteins
were mainly localized into the extracellular exosome, i.e., vesicles released in the extracellular region
(87% and 74%), as well as in the extracellular matrix (Table S4).
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Figure 4. Bioinformatic analyses of enriched secreted proteins. Biological processes, molecular functions
and cellular component of secreted proteins detected in (A) CM of R273H and in (B) CM of R175H
transfected AsPC-1 cells.
We have further explored the enriched pathways and functions that are associated with modulated
proteins quantified in the secretome by using the ClueGO app for Cytoscape platform. Only significant
pathways or terms were presented by setting the statistical threshold (p-value < 0.05) and using
the KEGG database as a reference. Figure 5 shows the functio ally grouped networks of regulated
proteins in the CM-R273H and CM-R175H samples. A blue term indicates an abundanc increas when
compared to the mock control, while a red term indicates an abundance decrease. Terms are linked based
on к-score (≥0.4), edge thickness indicates the association strength while node size corresponds to the
statistical significance for each term. The results show an over secretion of the endopeptidase inhibitor
activity and the down-regulation of systemic lupus erythematosus related-proteins for CM-R273H.
The analysis of CM-R175H sample reported an enrichment of proteins related to extracellular matrix
(also present in CM-R273H) and an interesting enrichment of proteins that are involved in the glycolysis
and gluconeogenesis, in agreement with the DAVID results.
STRING software was employed in order to investig fun tional and physical protein
interactions am g p53 and the differentially secreted proteins (Figure 6). Our analysis rev aled
that the following 11 proteins are clustered in a tight interaction network centered on p53: HMGA1,
HIST1H1C, YWHAZ, YWHAG, HSP90AB1, HSPB1, HSP90AA1, HSPA8, PRDX1, TXN, and NPM1.
Altogether these data allow for better understanding the complex network of proteins differentially
secreted by mutant p53 and their relative functions and potential interactions.
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Figure 5. Cytoscape-based ClueGo/CluePedia pathway analysis and visualization. The enriched
pathways were derived by the Kyoto Encyclopaedia of Genes and Genome (KEGG) database. The
figure reports the functionally grouped networks of regulated proteins in the R273H and R175H
transfected cell line. Blue term indicates an abundance increase compared to the mock control while
red term indicates an abundance decrease. Terms are linked based on к-score (≥0.4), edge thickness
indicates the association strength while node size corresponds to the statistical significance for each term.
Biological processes are represented with hexagons, cellular components with octagons, molecular
functions with triangles and KEEG pathways with circles.
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centered on p53.
4. Discussion
The TP53 gene is one of the most frequently mutated genes in cancers, especially in PDAC, and most
of its mutations are missense mutations in the DNA binding domain, resulting in the expression
of mutant isoforms of p53, which acquire new oncogenic properties, referred to as gain-of-function
(GOF) [9]. These novel functions are involved in a plethora of different cellular pathways that are
focused on cancer progression and aggressiveness, counteracting apoptosis, autophagy, and cellular
senescence, and promoting invasion, metastasis, and chemoresistance [11,39,40]. The influence of
mutant p53 in the clinical outcome of cancer patients, the high frequency of GOF mutations in the
TP53 gene, and the involvement of mutant p53 in a number of different cellular pathways have
stressed the need to deeply investigate the events that are associated to cancer progression driven by
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mutant p53 isoforms in molecular oncology. Here, we discovered that the secretome driven by mutant
p53 is able to favor cell growth and chemoresistance and counteract cell death-related mechanisms.
Thus, we investigated the secreted proteins modulated by mutant p53 and identified a number of
differentially secreted proteins by R175H (Supplementary Materials Table S1) or R273H (Supplementary
Materials Table S2) mutant p53 isoforms. Interestingly, we identified 15 proteins (listed in Table 1)
that were differentially secreted by both mutant p53 isoforms with the same trend of regulation.
The clinical impact in cancers of these proteins and their involvement in the modulation of cancer
microenvironment are discussed below.
Among mutp53-driven hyper-secreted proteins, we identified cofilin (COF1), which is involved
in tumor cell migration and invasion by promoting actin cytoskeleton reorganization and cell-cell
adhesion regulation and the level of cofilin-1 in patient’s sera is associated with PDAC progression
and poor prognosis [41–43]; calsyntenin-1 (CLSTN1), which plays a fundamental role in cellular
adhesion and cell communication and its expression level was increased in sera of patients with lung
adenocarcinoma or in ovarian adenocarcinoma cell lines, but the molecular mechanisms of CLSTN1
in cancer still need to be investigated [44–46]; vimentin (VIME), which is a well-known marker for
epithelial-mesenchymal transition (EMT), and elevated levels of circulating vimentin were detected
in hepatocellular carcinoma and in circulating tumor cells (CTCs) in PDAC. Notably, the presence of
vimentin+ CTCs was negatively associated with progression-free survival [47–49]. We also found that
both R273H and R175H p53 mutant isoforms favor the hyper-secretion of the tissue inhibitor matrix
metalloproteinase 1 (TIMP1) in PDAC cells. Matrix metalloproteases (MMPs) are able to impact tumor
cell behavior in vivo by several means: (i) the direct degradation of the stromal connective tissue and
basement membrane components, favoring the invasion and metastasis of cancer cells [50]; (ii) cleavage
of membrane-bound growth factors or cytokines as well as their receptors [51]; (iii) and, cleavage of
cell adhesion molecules, such as cadherins, leading to an increased cell motility occurring in EMT [52].
On the other hand, the activity of MMPs is specifically inhibited by TIMPs, but it is now assumed that
TIMPs are multifactorial proteins that are also involved in the induction of proliferation and inhibition
of apoptosis [53]. Eirò et al. found that subgroups of tumors showing a stromal molecular profile
of abundant MMPs and TIMPs expression are strongly associated with higher recurrence of distant
metastases. On the contrary, tumors with stromal phenotypes displaying low molecular profiles have
an excellent clinical outcome [54]. These are relevant findings when considering that MMPs are mainly
governed by the tumor stroma and they exert powerful influences on the local tissue microenvironment
during tumorigenesis and progression. In this context, we suggest that TIMP1 hypersecretion by tumor
cells expressing mutant p53 might further contribute to render the tumor microenvironment prone to
invasion or metastasis. Accordingly, TIMP1 is considered as a prognostic marker for cancer progression
and metastasis [55,56]. An increase in TIMP1 gene expression and secretion has been shown in PDAC
mouse models, as well as in human biopsies and serum [57]. The high serum concentration of TIMP1
is related to poor prognosis in ovarian cancer and in many other malignant tumors [57,58]. Our data
also revealed a strong hyper-secretion of insulin-like growth factor-binding protein 1 (IGFBP1) in
both R273H- and R175H-driven secretome samples. IGF signaling and p53 are strongly connected in
cancer, especially in relation to tumor development and progression [59]. IGFBP1 is also involved in
the activation of O-GlcNAcylation of FoxO1 in pancreatic β cells by promoting AKT inhibition [60]
in cancer cell response to DNA damage [61] and it promotes angiogenesis in glioblastoma [62].
Furthermore, high levels of serum IGFBP-1 were shown in patients with nasopharyngeal carcinoma
(NPC) and associated with poor prognosis [63]. In the secretome of both p53 mutants, we have also
observed the hyper-secretion of the endothelial protein C receptor (PROCR), which is implicated
in the carcinogenesis of various tumor types [64]. Indeed, PROCR has a tumor promoting effect
and its silencing in gastric cancer inhibits the proliferation and migration via the ERK1/2 pathway,
while, in ovarian cancer cells, it induces cell migration via MEK-ERK and Rho-GTPase pathways [65].
Interestingly, Wang et al. reported that IGF-1 receptor mediates the signaling function of PROCR
in breast cancer cells [66]. In particular, they demonstrated that PROCR induces the activation of
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ERK and PI3K–AKT–mTOR signal through the transactivation of IGF-1R by Src and concomitantly
stimulates RhoA–ROCK–p38 signals. In our system, we can hypothesize that the mutp53-dependent
secretion of both IGFBP1 and PROCR might act in synergy to trigger intracellular pathways that
are involved in cancer cell proliferation. Previous studies have suggested that PROCR+ cells have
increased EMT features [67]. In our study, we observed that mutp53-dependent secretome increased
the N/E cadherin ratio, which suggests the stimulation of EMT. Thus, PROCR might be another channel
through which mutp53-dependent secretome promotes EMT and tumor progression. By a clinical
perspective, PROCR can be considered to be a possible biomarker of cancer onset, since its secretion is
related to enhanced cell survival, invasion, and immune down regulation in patients with ovarian
cancer [68]. Dermcidin (DCD), ezrin (EZR), and prosaposin (PSAP) are also hyper-secreted in both
R273H- and R175H-driven secretome samples and they promote cancer progression [69–71]. Elevated
levels of DCD are associated with the early progression of breast cancer and metastatic progression
of melanoma [72,73]. EZR promotes the invasion and metastasis of pancreatic cancer cells. It might
provide a predictive and diagnostic signature in PDAC, but the mechanisms of ezrin-mediated tumor
development still require further elucidation [70,74]. PSAP is a conserved glycoprotein with multiple
functions and it is involved in the development of cancers [71,75]. In particular, in breast cancer,
mesenchymal stem cells induces prosaposin secretion to drive the proliferation [76]. Furthermore, the
serum-PSAP levels are increased in patients with advanced prostate cancer and this could provide a
cell survival response after therapeutic interventions [77].
Our study also revealed hypo-secretion of five types of histones in both mutant R273H- and
R175H-driven secretome samples. Besides nuclear functions, histones can act as endogenous danger
signals when they shift from the nucleus to the extranuclear space [78]. Indeed, in response to
apoptotic signals, histones translocate from genomic DNA to cytoplasm and they are then released
in the extracellular compartment [79]. Thus, our data suggest that the reduced secretion of histones
in mutp53-driven secretome samples might suggest one of several ways by which mutp53-driven
secretome inhibits cell death-related phenomena, such as apoptosis, in accordance with the antiapoptotic
role of intracellular mutant p53 isoforms [31].
5. Conclusions
Finally, these data show the key role of the TP53 gene in the network of the differentially secreted
proteins. We finally provide evidence that, in addition to the alteration of gene expression profile or
to the specific protein-protein intracellular interactions, the oncogenic role of mutant p53 can also
be due to a marked alteration of cancer secretome that can promote cancer aggressiveness in an
autocrine/paracrine manner and regulate the cancer–stroma relationship. Future investigations are
needed to further discover the role and biological impact in cancer microenvironment of the specific
proteins that are differentially secreted by mutant p53 and identified in the present study. Furthermore,
we will also aim to investigate whether some of these differentially secreted proteins may constitute a
secreted signature detectable in PDAC patients’ sera that can be easily predictive for GOF TP53 gene
mutations in cancer patients. This might also enable the identification of targeted therapies that are
specifically addressed to inhibit growth of PDACs carrying oncogenic mutant p53, which are strongly
resistant to traditional chemotherapies.
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